Ensysce Biosciences, Inc. (ENSC) stock
ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.38−0.03 (-6.28%)
Close on Nov 17, 2026Market cap $7.47MP/E –Yield –
Ensysce Biosciences cash
Cash and short-term investments held at the end of each period.
Ensysce Biosciences's cash was $676.70K at Jun 30, 2026. For fiscal 2025 it was $4.31M, up 23.1% from the year before. The highest annual figure on record is $12.26M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.31M | +23.1% |
| FY2024 | Dec 31, 2024 | $3.50M | +211.7% |
| FY2023 | Dec 31, 2023 | $1.12M | -64.3% |
| FY2022 | Dec 31, 2022 | $3.15M | -74.3% |
| FY2021 | Dec 31, 2021 | $12.26M | +6215.1% |
| FY2020 | Dec 31, 2020 | $194.21K | -81.7% |
| FY2019 | Dec 31, 2019 | $1.06M | -36.0% |
| FY2018 | Dec 31, 2018 | $1.66M | -20.7% |
| FY2017 | Dec 31, 2017 | $2.09M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $676.70K | -69.4% |
| Q1 FY2026 | Mar 31, 2026 | $745.48K | -75.6% |
| Q4 FY2025 | Dec 31, 2025 | $4.31M | +23.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.67M | -59.7% |
| Q2 FY2025 | Jun 30, 2025 | $2.21M | +112.0% |
| Q1 FY2025 | Mar 31, 2025 | $3.05M | -10.3% |
| Q4 FY2024 | Dec 31, 2024 | $3.50M | +211.7% |
| Q3 FY2024 | Sep 30, 2024 | $4.15M | +183.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.04M | -72.8% |
| Q1 FY2024 | Mar 31, 2024 | $3.40M | +140.5% |
| Q4 FY2023 | Dec 31, 2023 | $1.12M | -64.3% |
| Q3 FY2023 | Sep 30, 2023 | $1.46M | -67.5% |
| Q2 FY2023 | Jun 30, 2023 | $3.83M | +2.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.42M | -83.2% |
| Q4 FY2022 | Dec 31, 2022 | $3.15M | -74.3% |
| Q3 FY2022 | Sep 30, 2022 | $4.50M | -34.2% |
| Q2 FY2022 | Jun 30, 2022 | $3.73M | -53.4% |
| Q1 FY2022 | Mar 31, 2022 | $8.44M | +46705.8% |
| Q4 FY2021 | Dec 31, 2021 | $12.26M | +6215.1% |
| Q3 FY2021 | Sep 30, 2021 | $6.85M | +12697.6% |
| Q2 FY2021 | Jun 30, 2021 | $8.01M | +6367.2% |
| Q1 FY2021 | Mar 31, 2021 | $18.03K | -89.3% |
| Q4 FY2020 | Dec 31, 2020 | $194.21K | -81.7% |
| Q3 FY2020 | Sep 30, 2020 | $53.49K | -95.8% |
| Q2 FY2020 | Jun 30, 2020 | $123.88K | -91.2% |
| Q1 FY2020 | Mar 31, 2020 | $167.95K | -88.9% |
| Q4 FY2019 | Dec 31, 2019 | $1.06M | -36.0% |
| Q3 FY2019 | Sep 30, 2019 | $1.27M | -27.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.40M | -18.6% |
| Q1 FY2019 | Mar 31, 2019 | $1.51M | -20.8% |
| Q4 FY2018 | Dec 31, 2018 | $1.66M | -20.7% |
| Q3 FY2018 | Sep 30, 2018 | $1.75M | – |
| Q2 FY2018 | Jun 30, 2018 | $1.72M | – |
| Q1 FY2018 | Mar 31, 2018 | $1.90M | – |
| Q4 FY2017 | Dec 31, 2017 | $2.09M | – |
See a number that looks wrong?